Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Book Review
Brief Report
Case Letter
Case Report
Case Series
Commentary
Current Issue
Editorial
Erratum
Guest Editorial
Images
Images in Neurology
Images in Neuroscience
Images in Neurosciences
Letter to Editor
Letter to the Editor
Letters to Editor
Letters to the Editor
Media and News
None
Notice of Retraction
Obituary
Original Article
Point of View
Position Paper
Review Article
Short Communication
Systematic Review
Systematic Review Article
Technical Note
Techniques in Neurosurgery
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Book Review
Brief Report
Case Letter
Case Report
Case Series
Commentary
Current Issue
Editorial
Erratum
Guest Editorial
Images
Images in Neurology
Images in Neuroscience
Images in Neurosciences
Letter to Editor
Letter to the Editor
Letters to Editor
Letters to the Editor
Media and News
None
Notice of Retraction
Obituary
Original Article
Point of View
Position Paper
Review Article
Short Communication
Systematic Review
Systematic Review Article
Technical Note
Techniques in Neurosurgery
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Book Review
Brief Report
Case Letter
Case Report
Case Series
Commentary
Current Issue
Editorial
Erratum
Guest Editorial
Images
Images in Neurology
Images in Neuroscience
Images in Neurosciences
Letter to Editor
Letter to the Editor
Letters to Editor
Letters to the Editor
Media and News
None
Notice of Retraction
Obituary
Original Article
Point of View
Position Paper
Review Article
Short Communication
Systematic Review
Systematic Review Article
Technical Note
Techniques in Neurosurgery
View/Download PDF

Translate this page into:

Case Report
11 (
3
); 492-494
doi:
10.1055/s-0040-1713300

Primary Central Nervous System Lymphoma Presenting as Parkinsonism with Atypical MRI Findings and Elevated 14-3-3 Protein

Department of Neurology, Columbia University, New York, New York, United States
Department of Neurology, University of Missouri, Columbia, Missouri, United States

Elanagan Nagarajan, MD Department of Neurology, Columbia University New York, NY 10032 United States en2452@cumc.columbia.edu

Licence
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Private Ltd. and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare neoplasm with an incidence of 2 to 3% of all CNS malignancies. The diagnosis can be challenging, especially with atypical presentations. Movement disorders can be one of the rare presentations of PCNSL. Here, we present an unusual case of gradually progressing Parkinsonism with an elevation of cerebrospinal fluid (CSF) 14–3-3 protein and atypical imaging findings found to have PCNSL. A 76-year-old female patient presented with gait and intermittent speech difficulty. Initial workup revealed a contrast-enhancing lesion in the bilateral putamen and head of caudate without any mass effect. Her symptoms were rapidly progressed over 6 months and presented with mild dysarthria, bradykinesia, mild rigidity, and reduced left arm swinging. These features were consistent with Parkinsonism. The repeat imaging showed the progression of hyperintensities in the bilateral putamen. The patient underwent a stereotypic biopsy of the right caudate nucleus, which revealed PCNSL. She was treated with high-dose methotrexate and is currently in remission. Diagnosis of movement disorders remains clinical and rapid progression of symptoms, and atypical presentation must warrant further imaging and workup.

Keywords

14–3-3
primary CNS lymphoma
parkinsonism

Background

Primary central nervous system lymphoma (PCNSL) is a rare neoplasm accounting for 2 to 3% of CNS malignancies. Over the past few decades, there is an increasing incidence of PCNSL among immunocompetent patients, particularly in the age group of 60 to 70 years or older. It is an aggressive brain tumor with a poor prognosis.1 PCNSL is confined to the CNS and often disseminated to structures within the brain, spinal cord, ocular, and leptomeningeal layers. The clinical presentation varies, depending on the location of the tumor and the immunocompetency of the patient.2 Despite the involvement of basal ganglia in CNS lymphomas, only a handful cases have been reported with movement disorders like segmental dystonia, choreoathetosis, and Parkinson’s disease.3 4 5 6 7 8

We presented an unusual case of gradually progressing Parkinsonism with an elevation of CSF 14–3-3 protein and atypical imaging findings found to have PCNSL.

Case Presentation

A 76-year-old right-handed Caucasian female patient with a history of papillary carcinoma of thyroid, hypertension, and hypothyroidism referred to our center for the evaluation of speech and walking difficulties of 6 months. She got hospitalized at a different facility for bilateral lower extremity weakness and intermittent speech problems. CT scan of the head demonstrated subtle hyperdensities in the bilateral putamen. MRI of the brain showed bilateral putamen and head of caudate T2/fluid-attenuated inversion recovery (FLAIR) hyperintensities that had nonhomogenous contrast enhancement without mass effect. (Fig. 1A) Magnetic resonance angiogram and venogram did not reveal any significant vessel occlusions or cortical vein thrombosis. There was no evidence of carbon monoxide poisoning in the blood testing. With the progressive worsening of symptoms, she was referred to our clinic for an evaluation in early summer, when she was found to have mild dysarthria, bradykinesia, mild rigidity, and reduced left arm swinging. Subsequent MRIs 6 months and 8 months later (Fig. 1B C) showed the progression of the lesions with T1, T2 FLAIR hyperintensities and continued to show nonhomogenous enhancement of bilateral putamen regions (Figs. 2 3). Serum iron studies, liver function tests, paraneoplastic, vasculitis, hepatitis panels, toxic and heavy metal screening, HIV, and vitamin levels were found to be within normal limits/negative. Cerebrospinal fluid (CSF) analysis showed elevation of 14–3-3 protein (3.7 nanogram with cut off at 2.0), normal CSF cytology, and flow cytometry. She underwent a stereotactic biopsy of the right caudate nucleus, which showed NonHodgkin lymphoma, diffuse B cell type. The whole-body PET scan did not show extracranial lymphoma. The patient received high-dose methotrexate with remission for 4 months. She has a recurrence of lymphoma and received whole brain radiation therapy and is in remission for the past 4 months.

Fig. 1 First MRI of our patient 8 months before the diagnosis. (A) Isointensity to slight hypointensity in bilateral putamen in T1 sequence. (B) T2 FLAIR sequence showing bilateral putamen hyperintensities (fairly symmetric). (C) Postcontract MRI showing mild heterogenous enhancement of bilateral putamen regions. FLAIR, fluid-attenuated inversion recovery.

Fig. 1 First MRI of our patient 8 months before the diagnosis. (A) Isointensity to slight hypointensity in bilateral putamen in T1 sequence. (B) T2 FLAIR sequence showing bilateral putamen hyperintensities (fairly symmetric). (C) Postcontract MRI showing mild heterogenous enhancement of bilateral putamen regions. FLAIR, fluid-attenuated inversion recovery.

Fig. 2 MRI performed 6 months after symptoms appeared. (A) Progression of hypointensity in bilateral putamen in T1 sequence. (B) progression of T2 FLAIR sequence showing bilateral putamen hyperintensities (fairly symmetric). (C) Postcontract MRI showing progression of mild heterogenous enhancement of bilateral putamen regions. FLAIR, fluid-attenuated inversion recover.

Fig. 2 MRI performed 6 months after symptoms appeared. (A) Progression of hypointensity in bilateral putamen in T1 sequence. (B) progression of T2 FLAIR sequence showing bilateral putamen hyperintensities (fairly symmetric). (C) Postcontract MRI showing progression of mild heterogenous enhancement of bilateral putamen regions. FLAIR, fluid-attenuated inversion recover.

Fig. 3 (A–C) MRI shortly before tissue diagnoses confirming PCNSL. T1 and T2 FLAIR sequence of MRI showing hyper intensities in bilateral putamen and right caudate of basal ganglia. Also note similar non homogenous contrast enhancement of bilateral putamen and caudate nucleus of basal ganglia. FLAIR, fluid-attenuated inversion recovery; PCNSL, primary central nervous system lymphoma.

Fig. 3 (A–C) MRI shortly before tissue diagnoses confirming PCNSL. T1 and T2 FLAIR sequence of MRI showing hyper intensities in bilateral putamen and right caudate of basal ganglia. Also note similar non homogenous contrast enhancement of bilateral putamen and caudate nucleus of basal ganglia. FLAIR, fluid-attenuated inversion recovery; PCNSL, primary central nervous system lymphoma.

Discussion

Parkinsonism is a rare presentation of PCNSL, although basal ganglia involvement is common. Some of the unusual features of this case are the subacute Parkinsonian symptoms, atypical imaging features, and an elevation of 14–3-3 protein in CSF.

PCNSL commonly presents with rapidly progressive neurological deficits from solitary hemispheric masses (in immunocompetent individuals), occasionally stroke and cranial nerve deficits, and progressive encephalopathy (in immunocompromised patients)9 10 11. Our patient presented with bradykinesia and rigidity and fulfilled the diagnostic criteria for Parkinson’s disease proposed by Hughes AJ and et al.12 However, the red flags in our patient included abnormal MRI, which prompted further workup that included serology and CSF analysis for alternative diagnoses, which can present with Parkinsonism. Previous authors who presented cases with Parkinsonism as a symptom of basal ganglia lymphoma suggested interruption of striatal postsynaptic dopamine receptors.5 6 The unique features of our patient are that she did not have classic MRI findings of a PCNSL but later evolved to classic MRI findings with T1 and T2 FLAIR hyperintesities with homogenous contrast enhancement.13 Also, her CSF cytology and flow cytometry was negative for lymphoma, but her 14–3-3 protein was elevated with Creutzfeldt–Jakob disease in the differential diagnosis. 14–3-3 protein is found in neuronal cytoplasm, glia, and synaptic membranes of the brain. It plays a crucial role in signal transduction, neurotransmission and cell differentiation, and is released into CSF where there is extensive neuronal damage. False-positive results can be seen in patients with herpes simplex encephalitis, hypoxic brain damage, and atypical encephalitis, intracerebral metastases of bronchial carcinoma, metabolic encephalopathy, and progressive dementia of unknown cause14. In our case, it is false positive for PCNSL, which is also rare and was reported only in a few other HIV cases with PCNSL.

Conclusion

Parkinsonism is a clinical syndrome with a broad differential. The etiology of Parkinsonism is mainly clinical, based on a thorough history and clinical examination. Imaging studies are not always warranted. Our case is unique in that she had a subacute Parkinsonism with extrapyramidal signs for more than 6 months. She potentially could be diagnosed with Parkinson’s disease based on queen square brain bank criteria. However, her imaging findings propelled further diagnostic testing, leading to a diagnosis of PCNSL. This case emphasizes the importance of considering imaging studies early on in selected Parkinsonian disorders to look for alternative diagnoses.

Ethical Approval

This study was approved by the Institutional Board Review of the University of Missouri Health Care–Columbia.

Conflict of Interest

None declared.

Funding None.

References

  1. , , , et al . Challenges and opportunities in primary CNS lymphoma: A systematic review. Radiother Oncol. 2017;122(3):352-361.
    [Google Scholar]
  2. , , , , , . Primary CNS lymphoma in immunocompetent patients. Oncologist. 2009;14(5):526-539.
    [Google Scholar]
  3. , , , , . Reversible choreoathetosis in primary cerebral lymphoma: clinicoradiologic correlation. Eur Neurol. 2003;50(1):53-54.
    [Google Scholar]
  4. , , , , . Primary CNS lymphoma presenting as a choreic movement disorder followed by segmental dystonia. Mov Disord. 1988;3(4):320-325.
    [Google Scholar]
  5. , , , , , . Neoplastic Parkinsonism: An illustrative case report. Ann Indian Acad Neurol. 2013;16(3):437-439.
    [Google Scholar]
  6. , , , , , , . Parkinsonian syndrome and central nervous system lymphoma involving the substantia nigra. A case report. Acta Neuropathol. 1985;65:338-343. (3-4)
    [Google Scholar]
  7. , . (The Parkinsonian syndrome induced by intracranial space occupying lesions [author’s transl]) Nervenarzt. 1977;48(7):383-385.
    [Google Scholar]
  8. , , , , , , . Parkinsonism secondary to metastatic lesions within the central nervous system: a case report. J Med Case Reports. 2010;4:218.
    [Google Scholar]
  9. , , , et al . Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand. 1998;97(4):257-264.
    [Google Scholar]
  10. , , . Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410-2418.
    [Google Scholar]
  11. , , , et al . Primary CNS lymphoma in immunocompetent: a review of literature and our experience from Kashmir. Turk Neurosurg. 2011;21(1):39-47.
    [Google Scholar]
  12. , , , , . Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
    [Google Scholar]
  13. , , , , . MR imaging features of intracranial primary CNS lymphoma in immune competent patients. Cancer Imaging. 2014;14:22.
    [Google Scholar]
  14. , , , , . The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol. 1999;41(4):216-225.
    [Google Scholar]
Show Sections